• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

    2.440 -0.030 (-1.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,623,320
    Open 2.560
    Bid (Size) 2.490 (2,900)
    Ask (Size) 2.500 (200)
    Prev. Close 2.470
    Today's Range 2.385 - 2.590
    52wk Range 0.6925 - 4.175
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
    Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
    Via Stocktwits
    Topics Intellectual Property
    Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
    Via Chartmill

    Performance

    YTD
    -34.2%
    -34.2%
    1 Month
    -28.0%
    -28.0%
    3 Month
    -40.2%
    -40.2%
    6 Month
    -12.5%
    -12.5%
    1 Year
    +60.5%
    +60.5%

    More News

    Read More
    News headline image
    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Corstasis Therapeutics Inc.
    Via Business Wire
    News headline image
    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in The 2026 Citizens Life Sciences Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗
    Via Stocktwits
    News headline image
    Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
    Via Chartmill
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
    Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
    The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
    What is the current price of Esperion Therapeutics, Inc. - Common Stock?
    The current price of Esperion Therapeutics, Inc. - Common Stock is 2.440
    When was Esperion Therapeutics, Inc. - Common Stock last traded?
    The last trade of Esperion Therapeutics, Inc. - Common Stock was at 03/13/26 04:00 PM ET
    What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
    The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 69.00M
    How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
    Esperion Therapeutics, Inc. - Common Stock has 69M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.